A Phase 2 interventional study of Docetaxel and Cisplatin in Nasopharyngeal Neoplasms, sponsored by Sanofi. Completed at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2010-11-17.
Sponsored by Sanofi · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong — none open to participants now, 1 under way, none of them phase 3. Nasopharyngeal Neoplasms · Hong Kong.
Among the 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong, this one is the 4th largest by enrollment, is the only one that started in 2002, is one of 6 in phase 2, and was the 3rd registered.
226 studies on the registry are indexed under Nasopharyngeal Neoplasms; 42 are open to participants now.
Browse Nasopharyngeal Neoplasms studies →None of the 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong is open now. The open studies under Nasopharyngeal Neoplasms, anywhere →
Of the 32 Nasopharyngeal Neoplasms studies recruiting now, 9 (28%) set no upper age limit and 18 (56%) stop at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 1
First in 2002; this study’s year is marked. 1 started in 2002.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 61 is close to the median of 60 across 178 interventional studies indexed under Nasopharyngeal Neoplasms.
Median enrollment 44 across the 10 interventional studies. Of the 8 that completed or were terminated, 2 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 10 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,560 studies on the registry; 91 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
Sanofi has 3 studies filed under Nasopharyngeal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Nasopharyngeal Neoplasms with a site in Hong Kong that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Nasopharyngeal Neoplasms with a site in Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective:
To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.
Secondary objective:
To assess tumor control and survival
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neo-adjuvant Taxotere followed by cisplatin and radiotherapy
Drug: Docetaxel
Cisplatin and radiotherapy alone without neo-adjuvant chemotherapy
Drug: Cisplatin
Treatment response is evaluated by correlating findings on clinical examination, endoscopy, biopsy, Computed tomography or Magnetic resonance imaging as appropriate.
Time frame: From administration of drug to end of study
Adverse Events
Time frame: From administration of drug to end of study
The record gives a start of Dec 2002, a primary completion of Mar 2010 and a completion of Mar 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Docetaxel